Nancy Zhang is a trial lawyer with extensive experience in high stakes disputes focusing on patents, trade secrets, unfair competition, and breach of contract. Nancy’s experience also extends to handling disputes that arise from healthcare coverage and federal drug incentive programs, employment discrimination, malpractice and professional negligence, false advertising, and fraudulent transfer matters.
Since joining the firm in 2017, Nancy has been instrumental in essentially all aspects of the practice, from first chair at trial to strategic prelitigation client counseling. Nancy’s broad reach of technology includes commercialized drug products, small molecule and biologics, medical and laboratory technologies, and telecommunications. For over 15 years, Nancy has litigated across different jurisdictions, including district court, the Federal Circuit, the International Trade Commission, the U.S. Patent and Trademark, and arbitration.
With a degree in Molecular Cell Biology from the University of California, Berkeley, Nancy routinely manages life science matters, framing complex, cutting edge technology within the legal landscape. Her fluency in Mandarin Chinese and familiarity with Chinese business culture and practice further enhance her relationships with clients based in Asia.
Representative clients include Altor BioScience (now part of NantCell, Inc./ImmunityBio), Amyris, Inc., Halozyme Therapeutics, Inc., Maravai LifeSciences, Risen (Suzhou) Pharma Tech. Co. Ltd., Beijing Firefox Information Technology Ltd., Regor Therapeutics Inc., Bio-Rad Laboratories, Samsung Bioepis Co., Ltd., Vifor Fresenius Medical Care Renal Pharma Ltd., Mitsubishi Tanabe Pharma Corp., Janssen Pharmaceuticals, Inc., and Cubist Pharmaceuticals LLC (acquired by Merck & Co.).
- Obtained complete victory for Vifor Fresenius Medical Care Renal Pharma Ltd. in a pharmaceutical patent case against Teva Pharmaceuticals USA, Inc. As a result, Vifor Fresenius’s Velphoro® product will be protected from generic competition until July 2030.
- Represented Altor BioScience (now part of NantCell/ImmunityBio) to obtain favorable settlement in dispute relating to breach of contract and trade secret misappropriation involving molecules developed using the TOBI™ discovery platform. After the arbitration hearing, HCW Biologics agreed to transfer rights to certain molecules and intellectual property to ImmunityBio.
- Represented Bio-Rad on matter involving droplet technology patents in an ITC investigation, proving at trial that competitor infringed Bio-Rad’s patents, resulting in an exclusion order restricting the importation of competitor’s infringing devices.
- Obtained favorable settlement on behalf of Regor Therapeutics Inc. in trade secret case involving critical metabolic disease drugs, including a GLP-1 receptor agonist.
- Represented Beijing Firefox Information Technology in unfair competition, licensing, and breach of contract dispute against Mozilla to reach favorable settlement in arbitration.
- University of Chicago, The Law School
(J.D., 2011) - University of California, Berkeley
(B.A., Molecular Cell Biology, 2008)
(B.A., Rhetoric, 2008)
- The State Bar of California
- United States Court of Appeals for the Federal Circuit
- United States District Court:
- Northern District of California
- Southern District of California
- U.S. Patent and Trademark Office
- Mandarin
- Wilson Sonsini Goodrich & Rosati:
- Associate, 2011-2017
- "The New Hybrid Standard for Appellate Review in Claim Construction," The Intellectual Property Strategist, March 2015